Recently, athe present study and several others reported an elevated level of serum sDPP-4/CD26 in patients with type 2 diabetes and MASLD or MASH, ,18, 19, 20 suggesting that serum sDPP-4/CD26 may be considered a new biomarker for liver fibrosis and progressive MASH, especially cirrhosis. This evidence concerns the gene DPP4 and metabolic dysfunction-associated steatotic liver disease.